Performance of a Drug‐Specific Calibration Curve for Monitoring Treatment With Albutrepenonacog Alfa: A Multicenter Study in Argentina
International Journal of Laboratory Hematology · 2025
DOI: 10.1111/ijlh.14469 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Laboratory Hematology, 2025. Verfasst von Pablo Martínez und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hospital Interzonal Dr. José Penna, Bahía Blanca, Argentina. Hauptthemen laut MEDLINE: Drug Monitoring, Factor IX, Hemophilia B. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Introduction
Laboratory testing is important for ensuring treatment effectiveness of hemophilia B. The most widely used laboratory test to measure factor IX (FIX) activity is the modified activated partial thromboplastin time (aPTT, one‐stage clotting assay [OSA]). Concerns emerged about albutrepenonacog alfa (Idelvion) impact on laboratory measurement. We aimed to evaluate a product‐specific calibration curve for determining the activity of Idelvion in Argentina.
Methods
In our nationwide, prospective, noninterventional study, a product‐specific calibration standard (PCS) was prepared from a reconstituted vial. Commercial FIX‐deficient plasma (FIXdp) spiked with Idelvion was used as a normal control (NC:0.7 IU/mL) and low control (LC:0.1 IU/mL). A drug‐specific OSA calibration curve was constructed starting from 1.0 IU/mL, followed by serial dilutions. Thirteen different aPTT reagents were used.
Results
Thiry‐six results from 27 Care Centers were retrieved. Median (interquartile range [IQR]) NC local standard human plasma (LSH) and NC PCSs were 0.48 IU/mL (0.38–0.92) and 0.72 IU/mL (0.58–0.82), respectively. Coefficients of variation (CVs) for NC LSH and PCS were 44.6% and 24.8%, respectively; recovery rates (± 20%) were 22% and 83%. Median LC LSH and PCS were 0.09 IU/mL (0.07–0.13) and 0.10 IU/mL (0.07–0.13), respectively; CVs for LC LSH and PCS were 104.8% and 24.7%. Recovery rates (±30%) were 58% and 89%.
Conclusion
Idelvion‐specific calibration curve showed better performance and lower CV rates independently of the aPTT reagent or the platform used. Calibration using this specific standard might allow more laboratories to obtain acceptable FIX values when processing NC and LC levels and patients' plasmas.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hospital Interzonal Dr. José Penna, Bahía Blanca, Argentina.
- Asociación Argentina de Hemofilia y Desórdenes Asociados (A.A.H.D.A.), Rosario, Provincia de Santa Fe, Rosario, Argentina.
- Centro de Tratamiento de Hemofilia, Sanatorio Mayo, Córdoba, Argentina.
- Fundación de la Hemofilia de Santa Fe, Rosario, Argentina.
- Facultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Provincia de Santa Fe, Rosario, Argentina.
ORCID-Profile: Pablo Martínez, María Verónica Arrieta, Germán Alejandro Detarsio, Mariana Paula Raviola
Zitieren
APA
Martínez, P., Arrieta, M. V., Detarsio, G. A., & Raviola, M. P. (2025). Performance of a Drug‐Specific Calibration Curve for Monitoring Treatment With Albutrepenonacog Alfa: A Multicenter Study in Argentina. International Journal of Laboratory Hematology. https://doi.org/10.1111/ijlh.14469
Vancouver
Martínez P, Arrieta MV, Detarsio GA, Raviola MP. Performance of a Drug‐Specific Calibration Curve for Monitoring Treatment With Albutrepenonacog Alfa: A Multicenter Study in Argentina. International Journal of Laboratory Hematology. 2025. doi:10.1111/ijlh.14469
BibTeX
@article{Martnez2025,
author = {Martínez, Pablo and Arrieta, María Verónica and Detarsio, Germán Alejandro and Raviola, Mariana Paula},
title = {Performance of a Drug‐Specific Calibration Curve for Monitoring Treatment With Albutrepenonacog Alfa: A Multicenter Study in Argentina},
journal = {International Journal of Laboratory Hematology},
year = {2025},
doi = {10.1111/ijlh.14469}
}
EUVIMED